2. The following information will be entered and the
patient will be stratified by:
- Study centre
- Tumour type (Dukes C colon, high risk Dukes
B colon cancer & rectal cancer sub-groups)
- Type of adjuvant chemotherapy received
(exposed/not exposed to oxaliplatin)
3. The randomisation system will then determine the
treatment arm and provide the subject number to be
used for the patient.
4. The site monitor/CRA will be informed immediately
in the event that the web randomisation is not
successful.